REGULATION OF EMERGENCY PANDEMIC BIOTECHNOLOGY PRODUCTION SYSTEMS IN JAPAN

1. INTRODUCTION

Emergency pandemic biotechnology production systems in Japan involve the accelerated development, manufacture, quality control and distribution of vaccines, biological medicines, diagnostic products and other medical countermeasures during public-health emergencies.

These systems are essential for maintaining national health security, ensuring continuity of medical supplies and responding to emerging infectious diseases. However, emergency production must operate within legal requirements concerning pharmaceutical safety, manufacturing quality, biosecurity, clinical research, public procurement and equitable distribution.

Japan does not regulate emergency pandemic biotechnology production through one comprehensive statute. Instead, its regulatory framework combines the Pharmaceuticals and Medical Devices Act (PMD Act), Infectious Diseases Control Act, Act on Special Measures for Pandemic Influenza and New Infectious Diseases Preparedness and Response, Biosecurity-related legislation and administrative emergency-response mechanisms.

The central legal objective is to accelerate access to essential medical products without compromising scientific evidence, manufacturing quality, public accountability or human safety.

2. PRINCIPAL LEGISLATIVE FRAMEWORK

A. PHARMACEUTICALS AND MEDICAL DEVICES ACT (PMD ACT)

The PMD Act establishes Japan's principal framework for pharmaceutical manufacturing, marketing authorisation and quality assurance.

Emergency pandemic vaccines and biological products remain subject to applicable manufacturing and quality requirements. The Act provides regulatory mechanisms for product approval, manufacturing and marketing authorisation, inspections and post-marketing safety monitoring.

Japan also has special approval mechanisms, including the emergency approval system introduced through amendments to the PMD Act in 2022. These mechanisms can permit conditional and time-limited authorisation in qualifying circumstances where ordinary approval requirements cannot reasonably be completed.

B. ACT ON SPECIAL MEASURES FOR PANDEMIC INFLUENZA AND NEW INFECTIOUS DISEASES PREPAREDNESS AND RESPONSE

This legislation establishes the governmental framework for preparing for and responding to pandemic influenza and other qualifying infectious-disease emergencies.

It provides for national preparedness planning, coordination between central and local governments, emergency policy implementation and measures intended to maintain essential public services and medical supply systems.

C. INFECTIOUS DISEASES CONTROL ACT

The Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases provides the legal framework for infectious-disease surveillance, prevention and public-health responses.

Its provisions support governmental coordination during infectious-disease emergencies and complement the regulatory framework governing vaccines, diagnostics and other medical countermeasures.

D. BIOLOGICAL SAFETY AND RESEARCH GOVERNANCE

Relevant biotechnology research and manufacturing activities must comply with applicable biosafety, occupational safety, environmental and research-ethics requirements.

The Cartagena Act is relevant to regulated living modified organisms, while the Industrial Safety and Health Act establishes workplace safety obligations. Their applicability depends on the particular organism, activity and facility.